CLINICAL_TRIALS trial_result · 2021-05-07

Clinical Trial Update: A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension [Phase 3]

Phase 3 study of balovaptan in adults with autism spectrum disorder was terminated; results posted in 2021 with a 2-year open-label extension.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Hoffmann-La Roche | Conditions: Autism Spectrum Disorder | Phase 3 | Status: TERMINATED | Results posted: 2021-05-07